Vogenx Raises $81.3 Million in Nasdaq Initial Public Offering
Clinical-stage biopharmaceutical company Vogenx sold 6,250,000 shares at $13.00 each in an IPO that closed on August 13, 2026. JonesTrading acted as sole book-running manager.
ticker-vogx
1 storyCoverage